Amarin (ADR) (AMRN)
Commercializes icosapent ethyl for cardiovascular care through Vascepa and Vazkepa.
Something off on this page? Send us feedback.
Commercializes icosapent ethyl as Vascepa in the United States and Vazkepa abroad. The company relies heavily on the product, selling directly in the United States and through international partners.
Vascepa and Vazkepa are brands for icosapent ethyl, the cardiovascular therapy at the center of the business. Vascepa began with an FDA-approved use for adults with severe hypertriglyceridemia and later gained a defined cardiovascular-risk-reduction use.
Sales combine a direct U.S. operation with indirect distribution through international partners, including European and other markets. The company is not built around a broad drug-discovery portfolio.
Most revenue comes from Vascepa, keeping its economics substantially tied to one product. U.S. sales operate alongside generic competition after a court invalidated several patents protecting the original U.S. use.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $314.6M · Total debt $5.3M · Total assets $624.4M · Shareholders' equity $443.6M
- Revenue
- $42.2M
- Operating income
- −$12.0M
- Net income
- −$7.7M
No dividends on record.
| Institutions | 42.06% | 9.32M ADS | |
|---|---|---|---|
| 86 holders · as of Jun 30, 2026 | |||
| Insiders | 0.76% | 167.7K ADS | |
| 13 holders · as of Aug 3, 2026 | |||
| Other | 57.18% | 12.67M ADS | |
| remainder | |||
22.15M ADS (1 ADS = 20 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
1 position filed across a stock split leaves its adjustment unstated and stays out of the bar.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Sarissa Capital Management LPInstitution | 15.11% | 1.67M ADS · 1.67M ADS | as of Jun 30, 2026 |
Acadian Asset Management LLCInstitution | 6.51% | 720,984 ADS · 720,984 ADS | as of Jun 30, 2026 |
Kynam Capital Management, LPInstitution | 4.81% | 532,982 ADS · 532,982 ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 2.02% | 223,617 ADS · 223,617 ADS | as of Jun 30, 2026 |
Waterfront Wealth Inc.Institution | 1.93% | 213,949 ADS · 213,949 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Dr. Reddy's Laboratories (ADR)
Generic icosapent ethyl supplier in the U.S.
- Teva (ADR)
Generic icosapent ethyl supplier in the U.S.
- Amneal Pharmaceuticals
Licensed generic icosapent ethyl supplier in the U.S.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Amarin (ADR) | $13.82 | +2.52% | $278.8M | — | — | 1.5 | −42.0% |
| Dr. Reddy's Laboratories (ADR) | $12.61 | +1.65% | $10.33B | 29.8 | 33.6 | 3.0 | −15.5% |
| Teva (ADR) | $39.65 | −1.02% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Amneal Pharmaceuticals | $19.52 | −3.19% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Median | 41.4 | 19.6 | 2.7 | −0.8% |